CASC
RCUS icon

Coppell Advisory Solutions Corp’s Arcus Biosciences RCUS Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$4.14K – 863
2022
Q4 		$4.14K Buy
+200
New +$5.5K ﹤0.01% 749

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Coppell Advisory Solutions Corp's RCUS Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 200 shares — an estimated $4.14K sold.

Coppell Advisory Solutions Corp first reported a position in RCUS in Q4 2022 and held it in 1 quarter. The position peaked at $4.14K in Q4 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 200 Arcus Biosciences shares in Q1 2023, an estimated $4.14K.
  • Coppell Advisory Solutions Corp first reported a position in Arcus Biosciences in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's Arcus Biosciences position peaked at $4.14K in Q4 2022.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.